Nektar Therapeutics (NASDAQ:NKTR) Holdings Lifted by SG Americas Securities LLC

SG Americas Securities LLC boosted its holdings in Nektar Therapeutics (NASDAQ:NKTR) by 30.6% during the 4th quarter, Holdings Channel reports. The fund owned 101,687 shares of the biopharmaceutical company’s stock after acquiring an additional 23,829 shares during the quarter. SG Americas Securities LLC’s holdings in Nektar Therapeutics were worth $57,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently modified their holdings of the company. Invesco Ltd. raised its holdings in Nektar Therapeutics by 0.9% during the first quarter. Invesco Ltd. now owns 37,230,534 shares of the biopharmaceutical company’s stock worth $200,672,000 after purchasing an additional 339,040 shares in the last quarter. BlackRock Inc. raised its stake in shares of Nektar Therapeutics by 11.0% in the 3rd quarter. BlackRock Inc. now owns 35,050,519 shares of the biopharmaceutical company’s stock worth $112,159,000 after buying an additional 3,477,606 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Nektar Therapeutics by 12.4% in the 3rd quarter. Vanguard Group Inc. now owns 23,164,944 shares of the biopharmaceutical company’s stock worth $74,128,000 after buying an additional 2,559,732 shares in the last quarter. RA Capital Management L.P. acquired a new stake in shares of Nektar Therapeutics in the third quarter valued at $11,138,000. Finally, State Street Corp boosted its stake in Nektar Therapeutics by 50.5% during the second quarter. State Street Corp now owns 8,728,968 shares of the biopharmaceutical company’s stock valued at $33,170,000 after buying an additional 2,928,666 shares in the last quarter. 75.88% of the stock is owned by institutional investors and hedge funds.

Nektar Therapeutics Price Performance

Nektar Therapeutics stock opened at $1.24 on Monday. Nektar Therapeutics has a fifty-two week low of $0.41 and a fifty-two week high of $1.75. The firm’s 50 day simple moving average is $0.96 and its 200-day simple moving average is $0.68. The company has a market cap of $227.69 million, a P/E ratio of -0.85 and a beta of 0.90.

Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings data on Monday, March 4th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.01). Nektar Therapeutics had a negative return on equity of 96.80% and a negative net margin of 306.31%. The firm had revenue of $23.89 million for the quarter, compared to analysts’ expectations of $17.09 million. During the same quarter in the previous year, the firm posted ($0.32) earnings per share. On average, analysts expect that Nektar Therapeutics will post -0.93 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. Jefferies Financial Group increased their target price on shares of Nektar Therapeutics from $0.50 to $1.00 and gave the company a “hold” rating in a research note on Wednesday, March 6th. William Blair reiterated a “market perform” rating on shares of Nektar Therapeutics in a research report on Tuesday, March 5th. Finally, StockNews.com began coverage on Nektar Therapeutics in a report on Friday, January 26th. They issued a “hold” rating on the stock. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, Nektar Therapeutics has an average rating of “Hold” and a consensus price target of $3.50.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer.